Xeris Pharmaceuticals News

Press Release: Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 Conference call and webcast at 8:30am ET CHICAGO--(BUSINESS WIRE)--May 02, 2024-- Xeris Biopharma Holdings, Inc. (Nasda

Dow Jones07:00 ET

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Top Owners Are Retail Investors With 51% Stake, While 45% Is Held by Institutions

Yahoo FinanceApr 5 11:15 ET

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business WireApr 3 16:05 ET

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today

BusinesswireApr 2 07:00 ET

Xeris Gains as Oppenheimer Highlights Drug Technology

Seeking AlphaMar 28 13:11 ET

Xeris Biopharma Initiated at Outperform by Oppenheimer

Xeris Biopharma Initiated at Outperform by Oppenheimer

Dow JonesMar 28 07:02 ET

Express News | Oppenheimer Initiates Coverage On Xeris Biopharma Holdings With Outperform Rating, Announces Price Target of $5

Moomoo 24/7Mar 28 06:51 ET

ANGI, MLKN and KOD Are Among After Hour Movers

Seeking AlphaMar 27 16:50 ET

Xeris Pharmaceuticals(XERS.US) Director Buys US$9,720 in Common Stocks

$Xeris Pharmaceuticals(XERS.US)$ Director Schmid John P. purchased 4,500 shares of Common Stocks on Mar 14, 2024 at an average price of $2.16 for a total value of $9,720.Source: Announcement What is s

moomoo NewsMar 14 21:44 ET

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)

TipRanksMar 11 00:40 ET

Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results

Yahoo FinanceMar 9 09:14 ET

Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.

Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 7 06:23 ET

Express News | HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6

Moomoo 24/7Mar 7 06:13 ET

Xeris Biopharma Holdings Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 146.91% HC Wainwright & Co. $5.5 → $6 Maintains Buy 11/13/2023 126.34% HC Wainwright & Co. $6 →

BenzingaMar 7 06:12 ET

Xeris Biopharma Down Nearly 18%, On Track for Largest Percent Decrease Since June 2020 -- Data Talk

Xeris Biopharma Holdings, Inc. ( XERS ) is currently at $2.53, down $0.55 or 17.86% --Would be lowest close since Feb. 5, 2024, when it closed at $2.47 --On pace for largest percent decrease since J

Dow JonesMar 6 14:07 ET

Earnings Call Summary | Xeris Pharmaceuticals(XERS.US) Q4 2023 Earnings Conference

The following is a summary of the Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript:Financial Performance:Xeris reported a 49% y-o-y increase in total revenue reaching $164 million in 2023 and e

moomoo AIMar 6 13:37 ET · Conference Call

OCEA, RVSN and HOVR Among Mid-day Movers

Seeking AlphaMar 6 12:50 ET

Express News | Xeris Biopharma Holdings Shares Are Trading Lower After the Company Reported Q4 Financial Results

Moomoo 24/7Mar 6 10:54 ET

Xeris Biopharma Shares Drop After Weak 4Q Results

By Dean Seal Shares of Xeris Biopharma Shares dropped after the company's fourth quarter results came in below expectations. The stock was down 18% at $2.52 in recent trading. Shares are still up 8%

WSJMar 6 10:41 ET

BYSI, PHUN and DTSS Among Pre-market Losers

Seeking AlphaMar 6 08:24 ET